|Bid||173.01 x 100|
|Ask||173.60 x 200|
|Day's Range||172.41 - 174.72|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.50|
|Dividend & Yield||4.60 (2.67%)|
|1y Target Est||N/A|
Regeneron Pharmaceuticals (REGN) has been hot this year, so hot in fact that I recommended buying its shares in May, while Jack Hough this month reiterated his bullish call from more than a year ago. Regeneron has benefited from a positive ruling in its patent battle against Amgen (AMGN), and the launch of Dupixent.
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...
Esperion Therapeutics bempedoic acid may help lower bad cholesterol levels, but that doesn't guarantee it will be a blockbuster. For that to happen, it's going to require a plan.